Swedish medical device company Episurf Medical (NASDAQ: EPIS B) revealed on Wednesday that its Episealer Talus and Talus Osteotomy Guide now have the CE mark.

Episurf Medical's minimally invasive and individualised treatment alternatives are developed for treating localised cartilage injury in joints.

The company said Episealer Talus is an implant technology designed for osteochondral lesions of the talar dome of the ankle joint, while its Talus Osteotomy Guide is an individualised osteotomy guide that helps surgeons finding the correct position and depth of the cut when performing a medial malleolar osteotomy to access the talar dome.

Pål Ryfors, CEO Episurf Medical, commented: "We have been looking forward to this and we are enormously happy to finally have the CE mark in place. It is fantastic that we now offer our implant technology not only for knees but also for these difficult to treat ankle injuries. Of course, this is also a significant commercial opportunity for us."